Research graph
References from Analysis of clinical features and outcomes in a Chinese cohort with ALK fusion across pan-cancer: a retrospective study. Local targets link to admitted publications; unresolved targets remain external evidence.
Alk fusions in the pan-cancer setting: another tumor-agnostic target
10.1038/s41698-023-00449-x · 2023 · External reference
Catalog of 5' fusion partners in ALK-positive NSCLC circa 2020
10.1016/j.jtocrr.2020.100015 · 2020 · External reference
Eml4-ALK variants: biological and molecular properties, and the implications for patients
10.3390/cancers9090118 · 2017 · External reference
Eml4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries
10.1002/1878-0261.13446 · 2023 · External reference
Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer
10.1007/s12094-024-03481-w · 2024 · External reference
Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: a retrospective study
10.1016/j.cancergen.2022.11.005 · 2023 · External reference
Alk fusion partners impact response to ALK inhibition: differential effects on sensitivity, cellular phenotypes, and biochemical properties
10.1158/1541-7786.mcr-18-0171 · 2018 · External reference
Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: real-world outcomes from the GuardantINFORM database
10.1016/j.jtho.2024.07.009 · 2024 · External reference
Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced NSCLC in relation to EML4::ALK variant type and ALK with or without TP53 mutations
10.1016/j.jtho.2023.07.023 · 2023 · External reference
Concomitant ALK fusion and TP53/EGFR mutation lead to adverse prognostic outcome
10.1111/crj.70041 · 2024 · External reference
Eml4-ALK: update on ALK inhibitors
10.3390/ijms26010308 · 2025 · External reference
Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive NSCLC: interim analysis of a randomized, open-label, phase 3 study (INSPIRE)
10.1016/j.jtho.2024.01.013 · 2024 · External reference
Anaplastic lymphoma kinase fusions: roles in cancer and therapeutic perspectives
10.3892/ol.2018.9856 · 2019 · External reference
Clinical responses to crizotinib, alectinib, and lorlatinib in a metastatic colorectal carcinoma patient with ALK gene rearrangement: a case report
10.1200/po.20.00534 · 2021 · External reference
Alk rearrangement-positive pancreatic cancer with brain metastasis has remarkable response to ALK inhibitors: a case report
10.3389/fonc.2021.724815 · 2021 · External reference
Rapid and deep response to lorlatinib in pancreatic high-grade neuroendocrine carcinoma with a treatment emergent novel KANK1-ALK fusion
10.1200/po.22.00230 · 2023 · External reference
Alk-rearranged renal cell carcinoma: a multi-institutional study of 9 cases with expanding the morphologic and molecular genetic spectrum
10.1016/j.modpat.2024.100536 · 2024 · External reference
Activated ALK cooperates with N-Myc via Wnt/beta-catenin signaling to induce neuroendocrine prostate cancer
10.1158/0008-5472.can-20-3351 · 2021 · External reference
Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report
10.21037/tlcr-24-963 · 2025 · External reference
Case report: targeted therapy of Malignant pleural mesothelioma with anaplastic lymphoma kinase receptor tyrosine kinase gene fusion mutation by crizotinib
10.1177/03000605241287320 · 2024 · External reference
First report of SPECC1L::ALK fusion in medullary thyroid carcinoma with remarkable response to alectinib
10.1089/thy.2025.0017 · 2025 · External reference
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study
10.1002/ajh.25043 · 2018 · External reference
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
10.1038/s41467-025-57941-0 · 2025 · External reference
If it's a target, it's a pan-cancer target: tissue is not the issue
10.1016/j.ctrv.2024.102721 · 2024 · External reference
Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer
10.1200/jco.2015.65.873 · 2016 · External reference
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC
10.1016/j.lungcan.2021.06.012 · 2021 · External reference
Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study
10.1016/j.jtho.2019.03.007 · 2019 · External reference
The impact of clinical factors, ALK fusion variants, and BIM polymorphism on crizotinib-treated advanced EML4-ALK rearranged non-small cell lung cancer
10.3389/fonc.2019.00880 · 2019 · External reference
Emerging roles for the INK4a/ARF (CDKN2A) locus in adipose tissue: implications for obesity and type 2 diabetes
10.3390/biom10091350 · 2020 · External reference
TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis
10.1007/s00432-023-04924-7 · 2023 · External reference
Dual ALK and CDK4/6 inhibition demonstrates synergy against neuroblastoma
10.1158/1078-0432.ccr-16-1114 · 2017 · External reference
